This is a Plain Language Summary of Publication article (PLSP) from Future Oncology, the NAPOLI 3 study compared two chemotherapy combinations for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had not received prior treatment. It included 770 patients and tested a new combination, NALIRIFOX (four chemotherapy drugs), against the standard treatment, GemNabPac (two chemotherapy drugs). Researchers evaluated patient survival, time until cancer worsened, and treatment side effects.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial’ and was published in Lancet.

Visit the Lancet using the link to read the original article.